logo-loader
viewNetscientific PLC

NetScientific PLC - Board Change

RNS Number : 8012Z
NetScientific PLC
15 January 2020
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014

 

NetScientific plc

 

("NetScientific" or the "Company")

 

Board Change

 

Resignation of Ian Postlethwaite as CEO, CFO and Company Secretary

 

 

London, UK - 15 January 2020:  NetScientific plc (AIM: NSCI), the transatlantic healthcare IP commercialisation Group, today announces that Ian Postlethwaite yesterday served six months' notice to step down as CEO, CFO and Company Secretary. Ian's departure date is scheduled for July 14th 2020 in accordance with his service agreement, and to ensure an orderly transition. Ian is leaving NetScientific after four years to pursue other career opportunities. 

 

The Board is continuing with its strategy review to determine how best to optimise returns to shareholders and decide on the required management arrangements. The Board anticipates announcing the findings of that review in conjunction with the Company's results for the year ended 31 December 2019.

 

The Board intends to commence a process for future appointments following the conclusion of that review.

 

Sir Richard Sykes, Chairman of the NetScientific, said: "Ian's support has been valuable to NetScientific.  He has provided a safe pair of hands during this challenging time as we continue to make the most of our reduced central costs and maximise the potential in our remaining portfolio companies to deliver value to our shareholders.  The Board would like to put on record its gratitude to Ian for his contribution in the transitioning of NetScientific since he took over as CEO last year and previously as CFO, and we wish him every success in his future interests."

 

Commenting on his resignation, Ian Postlethwaite, added: "I have thoroughly enjoyed working with the team at NetScientific and truly believe that our portfolio companies hold great promise.  Following last year's changes, I have worked to transition the Company to a low cost operating model and have supported the development of its three key assets: with Glycotest Inc. concluding its Series A financing round with Shanghai Fosun Pharmaceutical Co. Ltd, PDS Biotechnology Corporation completing its all share merger with Edge Therapeutics, and ProAxsis forecasting to reach cash break-even this year.  "

 

For more information, please contact:

 

NetScientific

Tel: +44 (0)20 3514 1800

 

 

WH Ireland Limited (NOMAD, Financial Adviser and Broker)

Chris Fielding / Darshan Patel

Tel: +44 (0)20 7220 1666

 

 

About NetScientific

NetScientific PLC is a transatlantic healthcare IP commercialisation Group focused on technologies and companies that have the potential to treat chronic disease and significantly improve the health and well-being of people. 

 

For more information, please visit the website at www.NetScientific.net

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
BOAEAXFLFDKEEFA

Quick facts: Netscientific PLC

Price: 2.7

Market: AIM
Market Cap: £2.12 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: ANGLE reports positive data from Parsortix FDA clinical study

Top stories from the Proactive Investors UK newsroom: ANGLE PLC (LON:AGL) has received positive results from its Parsortix FDA clinical study for metastatic breast cancer. The 400-subject clinical study will support an application for Class II regulatory clearance for Parsortix in the...

on 31/5/19